

Changing the face of COPDcare

Media infographic

45 years of experience

GSK has been working to improve the management of respiratory disease for over **45** years.¹ Since 2013 we have gained FDA approval for **4** new medicines for Chronic Obstructive Pulmonary Disease (COPD)¹ making them available in many countries worldwide.



Evolving our COPD portfolio

We are currently investigating a further **6** potential medicines for COPD³ including:

- An **anti-interleukin 5** treatment for severe COPD
- A **chemokine receptor 2 antagonist** for COPD




Precedent-setting research

Our landmark trials, including two of the largest COPD studies ever undertaken, help inform scientific understanding of COPD management: **Salford Lung Study in COPD⁴, SUMMIT⁵, ECLIPSE⁶, IMPACT.⁷**



Broadest range of once-daily inhaled COPD treatments

Individual patients have different needs and in COPD these can change over time. We don't believe in a "one size fits all" approach. We aim to provide the right medicine, for the right patient. We focus on the key areas of patient need in line with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report²:



- **Treat symptoms**
- **Reduce risk of exacerbations**

We have the broadest range of once-daily treatments for COPD which are delivered using the same type of inhaler. This offers patients the continuity of using the Ellipta inhaler if their treatment needs to be changed.

Beyond medicine development

We have delivered patient support tools and services to further enhance care.⁸

- **COPD.com:** GSK's website dedicated to COPD awareness, which offers patients and caregivers resources to learn about COPD. By signing up for the free self-care kit, patients can be better prepared to manage their symptoms.



[More info](#)

Changing the face of COPDcare

Media infographic

Exploring emerging scientific concepts



We are relentless in our work to set precedents in discovering and developing medicines

That meet patient needs. This includes innovating in our research to explore emerging scientific concepts:

- **ECLIPSE:** the largest study to investigate subtypes of COPD and predictive markers of its progression.⁶
- **Clinically important deterioration:** reviewing our data to explore whether early

treatment can bring greater disease stability by reducing the potential for ‘clinically important deteriorations’ which may represent a worsening of a patient’s COPD.⁹

- **Treatable traits:** exploring whether blood eosinophil levels may indicate whether a patient will benefit more from certain types of COPD treatment.⁷

The data and insights from our research, alongside our early phase scientific discovery, give us the potential to continue to transform the way COPD is managed well into the future.

References (all links accessed August 2017)

1. GSK. 50 years of R&D innovation. Available at: <http://www.gsk.com/media/1287/50-years-of-randd-innovation.pdf>
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: <http://goldcopd.org>
3. GSK. Product pipeline. Available at: <http://gsk.com/en-gb/research/what-we-are-working-on/product-pipeline/>
4. Vestbo J, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. NEJM 2016; 375:1253-60
5. Vestbo J, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet 2016; 387: 1817-1826
6. Vestbo J, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Resp J 2008; 31: 869-873. ECLIPSE publications available at: <http://www.eclipse-copd.com/home.aspx>
7. Pascoe SJ, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Resp J 2016; 48: 320-330
8. Jones PJ, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654 GSK
9. Singh D et al. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. International Journal of COPD 2016;11 1413-1424